VVT Medical recently announced that the American Venous Forum (AVF) has provided an official opinion letter regarding CPT coding guidance for the ScleroSafe percutaneous endovenous ablation procedure. This procedure, which combines mechanical collapse and chemical ablation to treat incompetent varicose veins, is now supported by existing CPT codes 36473 and 36474.
A press release includes the following CPT code descriptors:
- 36473: Endovenous ablation therapy of incompetent vein extremity inclusive of all imaging guidance and monitoring percutaneous mechanochemical; first vein treated.
- 36474: Endovenous ablation therapy of incompetent vein extremity inclusive of all imaging guidance and monitoring percutaneous mechanochemical; subsequent vein(s) treated in a single extremity each through separate access sites.
The AVF Health Policy Committee convened on 13 August 2024 to review and discuss the ScleroSafe device. The committee confirmed that the procedures performed using the ScleroSafe device are accurately described by the current CPT codes 36473 and 36474, which cover endovenous ablation therapy of incompetent vein extremities, inclusive of all imaging guidance and monitoring.
View the official letter from the AVF Health Policy Committee here.
ScleroSafe has been cleared by the US Food and Drug Administration (FDA) under the 510(k) process, with its predicate device being Clarivein. The ScleroSafe device utilises mechanical disruption and abrasion of the venous intima, combined with the infusion of a physician-specified sclerosant using the ScleroSafe dual procedure syringe/catheter system. This approach provides a comprehensive solution for treating varicose veins, VVT Medical claims.
“We are delighted with the AVF’s endorsement, which provides clear and accurate coding guidance for physicians utilising ScleroSafe™ in their practice,” said Erez Tetro, chief executive officer of VVT Medical. “This is a significant step forward in our mission to enhance the treatment of varicose veins and ensure that our healthcare partners are well supported in providing high-quality care. This achievement was made possible with the support of our US partner, Methapharm, and our leading key opinion leaders (KOLs), who have been instrumental in guiding this process and ensuring the device’s alignment with current CPT codes.”
